Home - ClinicalTrials.gov...Protocol Date: December 16, 2015 Statistical Analysis Plan (SAP) Date:...

Preview:

Click to see full reader

Citation preview

  •          

                  

  •    

       

       

       

       

                   

       

       

             

          

          

                

          

       

                      

       

       

       

     

     

  •    

           

               

           

          

       

       

       

         

     

Recommended

Allergan v. Sandoz
Documents
PROTOCOL SYNOPSIS - ClinicalTrials.gov · This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs
Documents
Amendment - ClinicalTrials.gov
Documents
GILEAU - ClinicalTrials.gov
Documents
Statistical Analysis Plan - ClinicalTrials.gov · 2018. 8. 6. · RUC SAP 08Nov2017.docx Statistical Analysis Plan jCyte, Inc. Protocol JC-01 A Prospective, Multicenter, Open-Label,
Documents
USC-ALLERGAN FELLOWSHIP PROGRAMpharmacyschool.usc.edu/files/2016/08/USC-Allergan-Fellowship...USC-Allergan Fellowship Program 2017 - 2018 Allergan plc (NYSE: AGN), headquartered in
Documents
Allergan Biostatistics Analysis Plan Clinical Study Report€¦ · Allergan Biostatistics Analysis Plan – Clinical Study Report Study ID: CMO-US-GI-0429 Study Title: A Phase 4 Multicenter,
Documents
PRADO - ClinicalTrials.gov
Documents
This is Allergan Brochure_072016
Documents
Titlpage - ClinicalTrials.gov
Documents
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO … · bo . Allergan C Setipipran t This SA P treatmen t Finasteri group w i onfidential Tablets is based on arms – Seti de 1 mg QD
Documents
Glaucoma Pocket Practice Guide - Allergan · Provided compliments of Allergan, makers of: Glaucoma Pocket Practice Guide 2nd Edition For the Ophthalmic Technician ©2010 Allergan,
Documents
REP0114 - clinicaltrials.gov
Documents
$PHQGPHQW - ClinicalTrials.gov
Documents
VIVID - clinicaltrials.gov
Documents
2016 ALLERGAN SUSTAINABILITY PERFORMANCE REPORT...2011–2015 Allergan Strategic Performance Goals & Results 7 Allergan’s 2020 Goals 7 ... Allergan plc is a bold, global pharmaceutical
Documents
Date of the document: 17 Nov 2015. - clinicaltrials.gov · Otsuka Pharmaceutical Development & Commercialization, Inc. Investigational New Drug OPC-41061 A Phase 3b, Multicenter,
Documents
USC-ALLERGAN FELLOWSHIP PROGRAM...2018/09/19  · USC-Allergan Fellowship Program 2018 - 2019 USC-Allergan Fellowship Program 2018 - 2019 Allergan plc (NYSE: AGN), headquartered in
Documents
ABCD - ClinicalTrials.gov · Secondary objective:to describe the profile of uncontrolled patients Study design: This observational multicenter and cross-sectional study will be conducted
Documents
Allergan 2010 Annual Report
Documents